Close Menu

Tecan

Following Illumina's acquisition of digital microfluidics firm Advanced Liquid Logic last month, the company is now planning how it will integrate ALL's electrowetting technology into new sequencing sample preparation products and evaluating what other applications to pursue that

Affymetrix has been awarded US Patent No. 8,492,121, "Complexity management of genomic DNA."
Shoulian Dong is named as the inventor.

Sony of Tokyo has received US Patent No.

Asuragen of Austin, Texas, has received US Patent No. 8,465,914, "Method and compositions involving microRNA." Methods are claimed for isolating, enriching, and labeling miRNA molecules, and for preparing and using arrays or other detection techniques for miRNA analysis.

Canon has been awarded US Patent No. 8,466,272, "Probe set and method for identifying HLA allele."
Mamoru Tsukada has been named as inventor on the patent.

NEW YORK (GenomeWeb News) – Illumina today said that it has launched a partnership program aimed at developing automation methods for its TruSeq and Nextera Sample Preparation kits.

Swift Biosciences has launched Accel-NGS DNA Library Kit, a PCR-free library prep kit that requires 5 nanograms of input DNA.

Austrian tools vendor Tecan announced this week that Arizona State University researchers have acquired one of its hybridization systems and two of its scanners for the purpose of processing protein microarrays.

Eppendorf recently launched the Mastercycler Nexus X1, the latest addition to the company's Mastercycler range of PCR instruments.

Akonni Biosystems has been awarded US Patent No. 8,334,117, "Temperature control device with a flexible temperature control surface."

Pages

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.